Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Atzpodien

Showing results (11-20 of 116) with videos related to

Pageof 12
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|October 18, 2001
13cis- and all-trans retinoic acid have antiproliferative effects on CML cells and render IFN alpha antiproliferative potency after combined treatment in vitroM Benthin, I Dallmann, J Atzpodien
Critical Reviews in Oncology/Hematology|August 24, 2005
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinomaJ Atzpodien, T Wandert, M Reitz
British Journal of Cancer|June 1, 2006
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinomaP Royston, M Reitz, J Atzpodien
Anticancer Research|September 1, 1995
Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patientsS Duensing, J Grosse, J Atzpodien
Cancer Biotherapy|January 1, 1995
Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinomaE Lopez Hanninen, H Poliwoda, J Atzpodien
World Journal of Urology|January 1, 1995
Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccinesH H Kirchner, P Anton, J Atzpodien
The Journal of Urology|January 1, 1996
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patientsE Lopez Hänninen, H Kirchner, J Atzpodien
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]H H Kirchner, J Atzpodien, H Poliwoda
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000
Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell linesS Duensing, A Duensing, J Grosse, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Cytokines and tumor vaccinationP Anton, H Kirchner, U Jonas, et al.
Pageof 12

Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Cancer Biotherapy & Radiopharmaceuticals|October 18, 2001
13cis- and all-trans retinoic acid have antiproliferative effects on CML cells and render IFN alpha antiproliferative potency after combined treatment in vitroM Benthin, I Dallmann, J Atzpodien
Critical Reviews in Oncology/Hematology|August 24, 2005
Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinomaJ Atzpodien, T Wandert, M Reitz
British Journal of Cancer|June 1, 2006
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinomaP Royston, M Reitz, J Atzpodien
Anticancer Research|September 1, 1995
Increased serum levels of basic fibroblast growth factor (bFGF) are associated with progressive lung metastases in advanced renal cell carcinoma patientsS Duensing, J Grosse, J Atzpodien
Cancer Biotherapy|January 1, 1995
Interferon-alpha/5-fluorouracil: a novel outpatient chemo/immunotherapy for progressive metastatic renal cell carcinomaE Lopez Hanninen, H Poliwoda, J Atzpodien
World Journal of Urology|January 1, 1995
Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccinesH H Kirchner, P Anton, J Atzpodien
The Journal of Urology|January 1, 1996
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patientsE Lopez Hänninen, H Kirchner, J Atzpodien
Medizinische Klinik (Munich, Germany : 1983)|April 12, 1996
[Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]H H Kirchner, J Atzpodien, H Poliwoda
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2000
Loss of VLA-3 (CD49c/CD29) expression in two multidrug resistant Burkitt's lymphoma cell linesS Duensing, A Duensing, J Grosse, et al.
Cancer Biotherapy & Radiopharmaceuticals|October 1, 1996
Cytokines and tumor vaccinationP Anton, H Kirchner, U Jonas, et al.
Pageof 12